Velan Capital Investment Management
Latest statistics and disclosures from Velan Capital Investment Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PRAX, CDTX, TARA, HRTX, MPLT, and represent 51.81% of Velan Capital Investment Management's stock portfolio.
- Added to shares of these 10 stocks: MPLT (+$9.2M), EVMN (+$8.7M), ESPR, VRCA, TARA, STRO, PROF, KZIA, TERN, RAPT.
- Started 9 new stock positions in MPLT, ESPR, PROF, STRO, VRCA, EVMN, KZIA, Trevi Therapeutics, XLO.
- Reduced shares in these 10 stocks: PRAX (-$9.4M), ZOOZ, ALMS, Sutro Biopharma, QURE, TELA, ELDN, MLYS, CRBP, TRML.
- Sold out of its positions in ACRS, ALEC, ALMS, ELDN, ERAS, GERN, Sutro Biopharma, TELA, TRML, ZOOZ. QURE, WVE.
- Velan Capital Investment Management was a net buyer of stock by $16M.
- Velan Capital Investment Management has $172M in assets under management (AUM), dropping by 61.93%.
- Central Index Key (CIK): 0001848809
Tip: Access up to 7 years of quarterly data
Positions held by Velan Capital Investment Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Velan Capital Investment Management
Velan Capital Investment Management holds 46 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines I Com New (PRAX) | 17.2 | $30M | -24% | 101k | 294.74 |
|
| Cidara Therapeutics Com New (CDTX) | 13.9 | $24M | 108k | 220.89 |
|
|
| Protara Therapeutics Com Stk (TARA) | 8.8 | $15M | +32% | 2.8M | 5.33 |
|
| Heron Therapeutics (HRTX) | 6.6 | $11M | 8.8M | 1.30 |
|
|
| Maplight Therapeutics (MPLT) | 5.3 | $9.2M | NEW | 522k | 17.57 |
|
| Abivax Sa Sponsored Ads (ABVX) | 5.2 | $9.0M | +4% | 67k | 134.85 |
|
| Evommune Com Shs (EVMN) | 5.0 | $8.7M | NEW | 507k | 17.12 |
|
| Mineralys Therapeutics (MLYS) | 3.2 | $5.5M | -14% | 151k | 36.29 |
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 2.9 | $5.0M | 75k | 66.55 |
|
|
| Jasper Therapeutics Com New (JSPR) | 2.8 | $4.9M | 2.7M | 1.83 |
|
|
| Avalo Therapeutics Com New (AVTX) | 2.8 | $4.8M | 264k | 18.16 |
|
|
| Esperion Therapeutics (ESPR) | 2.6 | $4.5M | NEW | 1.2M | 3.70 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 2.3 | $3.9M | NEW | 472k | 8.31 |
|
| Inspiremd (NSPR) | 2.2 | $3.8M | 2.1M | 1.78 |
|
|
| Rapt Therapeutics Com New (RAPT) | 2.1 | $3.7M | +35% | 108k | 33.87 |
|
| Sutro Biopharma Com Shs (STRO) | 2.1 | $3.6M | NEW | 312k | 11.57 |
|
| Terns Pharmaceuticals (TERN) | 1.6 | $2.8M | +250% | 70k | 40.40 |
|
| Syndax Pharmaceuticals (SNDX) | 1.6 | $2.7M | 130k | 21.01 |
|
|
| Miragen Therapeutics (VRDN) | 1.6 | $2.7M | 87k | 31.12 |
|
|
| Eupraxia Pharmaceuticals (EPRX) | 1.5 | $2.7M | 352k | 7.55 |
|
|
| Trevi Therapeutics (TRVI) | 1.5 | $2.6M | 205k | 12.52 |
|
|
| Profound Med Corp Com New (PROF) | 1.3 | $2.2M | NEW | 286k | 7.87 |
|
| Kazia Therapeutics Sponsored Ads (KZIA) | 1.2 | $2.1M | NEW | 300k | 6.89 |
|
| Rezolute Com New (RZLT) | 1.0 | $1.8M | 750k | 2.36 |
|
|
| Tenax Therapeutics Com New (TENX) | 0.6 | $1.0M | 83k | 12.19 |
|
|
| Edesa Biotech Com New (EDSA) | 0.6 | $976k | 688k | 1.42 |
|
|
| Trevi Therapeutics Call Call Option | 0.3 | $482k | NEW | 39k | 12.52 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.3 | $432k | 6.5k | 66.39 |
|
|
| Ventyx Biosciences (VTYX) | 0.2 | $361k | 40k | 9.03 |
|
|
| Cytomx Therapeutics (CTMX) | 0.2 | $341k | 80k | 4.26 |
|
|
| Protagonist Therapeutics (PTGX) | 0.2 | $323k | 3.7k | 87.34 |
|
|
| Nurix Therapeutics (NRIX) | 0.2 | $304k | 16k | 18.97 |
|
|
| Ovid Therapeutics (OVID) | 0.2 | $261k | 160k | 1.63 |
|
|
| Gossamer Bio (GOSS) | 0.1 | $217k | 70k | 3.10 |
|
|
| Immunome (IMNM) | 0.1 | $215k | 10k | 21.48 |
|
|
| Design Therapeutics (DSGN) | 0.1 | $188k | 20k | 9.38 |
|
|
| Immix Biopharma (IMMX) | 0.1 | $183k | 35k | 5.23 |
|
|
| Context Therapeutics (CNTX) | 0.1 | $147k | 100k | 1.47 |
|
|
| Replimune Group (REPL) | 0.1 | $146k | -25% | 15k | 9.72 |
|
| Larimar Therapeutics (LRMR) | 0.1 | $126k | 33k | 3.81 |
|
|
| Xilio Therapeutics (XLO) | 0.1 | $109k | NEW | 170k | 0.64 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.1 | $106k | -78% | 13k | 8.14 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.1 | $91k | 45k | 2.02 |
|
|
| Precision Biosciences Com New (DTIL) | 0.0 | $83k | 20k | 4.16 |
|
|
| Pyxis Oncology Common Stock (PYXS) | 0.0 | $46k | -27% | 40k | 1.15 |
|
| Pmv Pharmaceuticals (PMVP) | 0.0 | $44k | 35k | 1.25 |
|
Past Filings by Velan Capital Investment Management
SEC 13F filings are viewable for Velan Capital Investment Management going back to 2021
- Velan Capital Investment Management 2025 Q4 filed Feb. 13, 2026
- Velan Capital Investment Management 2025 Q3 filed Nov. 14, 2025
- Velan Capital Investment Management 2025 Q2 filed Aug. 14, 2025
- Velan Capital Investment Management 2025 Q1 filed May 15, 2025
- Velan Capital Investment Management 2024 Q4 filed Feb. 14, 2025
- Velan Capital Investment Management 2024 Q3 filed Nov. 14, 2024
- Velan Capital Investment Management 2024 Q2 filed Aug. 14, 2024
- Velan Capital Investment Management 2024 Q1 filed May 14, 2024
- Velan Capital Investment Management 2023 Q3 filed Nov. 13, 2023
- Velan Capital Investment Management 2023 Q2 filed Aug. 11, 2023
- Velan Capital Investment Management 2023 Q1 filed May 15, 2023
- Velan Capital Investment Management 2022 Q4 filed Feb. 13, 2023
- Velan Capital Investment Management 2022 Q3 filed Nov. 14, 2022
- Velan Capital Investment Management 2022 Q2 filed Aug. 15, 2022
- Velan Capital Investment Management 2022 Q1 filed May 16, 2022
- Velan Capital Investment Management 2021 Q4 filed Feb. 14, 2022